Publications by authors named "Kiran K Matta"
Article Synopsis
- CDX2 is a crucial nuclear protein for intestinal cell growth, and its down-regulation is often observed in colorectal cancer (CRC), which can impact patient prognosis.
- In a study of 110 CRC patients, CDX2 expression was analyzed, revealing that 66.4% were positive for CDX2, while its loss correlated with advanced cancer stages and poorer differentiation.
- Patients without CDX2 showed significantly reduced progression-free survival (30%) and overall survival (46%) compared to those with CDX2 expression, indicating it may serve as a negative prognostic marker in CRC.
Background: Limited information is available on changing trends in HIV positive patients treated with first-line antiretroviral therapy from India.
Methods: The clinical characteristics and short-term outcome were compared between a retrospective group enrolled between January 2006 and March 2007 (06-07 group-100 patients) and a prospective group enrolled between February 2011 and March 2012 (10-12 group-85 patients).
Results: Median age was 36 and 38 years in 06-07 and 10-12 groups, respectively.
Purpose: Beta lactams are standard empirical therapy for febrile neutropenia (FN). The aim of this study was to evaluate the efficacy and safety of cefepime monotherapy compared with cefoperazone/sulbactam plus amikacin (CS + A) for empirical treatment of high risk FN.
Methods: One hundred seventy-five patients with 336 FN episodes were randomized to receive either cefepime (2 g q8h for adults and 50 mg/kg q8h for children) or CS (2 g q8h for adults and 50 mg/kg q8h for children) plus amikacin (15 mg/kg once a day).